Could a liver cancer drug slow eye cancer spread?
NCT ID NCT02517736
First seen Feb 18, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This study tested the drug sorafenib (Nexavar) in 32 adults with uveal melanoma that had spread to other parts of the body. The goal was to see if the drug could stop tumors from growing for at least 24 weeks. Sorafenib is already used for other cancers, and researchers wanted to know if it could help control this rare eye cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service d'ophtalmologie, CHU de Caen
Caen, 14000, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sorafenib (Nexavar)
What this could lead to
If successful, sorafenib could offer a treatment option to slow tumor growth in patients with metastatic uveal melanoma.
What could go wrong
This is a small Phase 2 trial with only 32 participants, so results may not apply broadly. Sorafenib can cause side effects like fatigue, diarrhea, and skin reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.